Story

Cencora Stock Slides Over 4% on Walgreens Volume Shift

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20261 min read
Cencora Stock Slides Over 4% on Walgreens Volume Shift
Text size
Background

Cencora (NYSE: COR) shares fell more than 4% in afternoon trading after the pharmaceutical distributor confirmed that some business volume from Walgreens has started to shift to rivals.

Details of the Volume Shift

Cencora disclosed that certain volumes from Walgreens, which were handled outside of its main prime vendor agreement, began moving to competing distributors as of July 1, 2026. The company stressed that its core prime vendor agreement, which constitutes the majority of its relationship with the pharmacy giant, remains fully intact.

Management sought to reassure investors by reaffirming its full-year fiscal 2026 adjusted diluted EPS guidance of $17.75 to $17.95. Cencora stated this volume shift was anticipated and had already been factored into its fourth-quarter commentary issued on August 5.

Sample IUX Markets – In-articleAd

Market Reaction and Context

The stock's 4.2% decline was a company-specific event, standing in contrast to the broader market's gains, with the S&P 500 up 0.3% during the session. The news appeared to unnerve investors who view the Walgreens relationship as a key component of Cencora's business stability.

Other factors also weighed on sentiment. The confirmation of lost volume overshadowed a positive analyst action from Wells Fargo, which had raised its price target on Cencora to $395 from $331 while maintaining an Overweight rating. Additionally, a previously disclosed plan by outgoing CFO James Cleary to sell approximately 20,000 shares added to investor caution.

Read next

More on Stocks
Back to latest news

LATEST